Linked Life Data

17484137

Source:http://linkedlifedata.com/resource/pubmed/id/17484137

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17484137rdf:typepubmed:Citationlld:pubmed
pubmed-article:17484137lifeskim:mentionsumls-concept:C0019704lld:lifeskim
pubmed-article:17484137lifeskim:mentionsumls-concept:C0040649lld:lifeskim
pubmed-article:17484137lifeskim:mentionsumls-concept:C0679199lld:lifeskim
pubmed-article:17484137lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:17484137lifeskim:mentionsumls-concept:C0851285lld:lifeskim
pubmed-article:17484137lifeskim:mentionsumls-concept:C0302350lld:lifeskim
pubmed-article:17484137pubmed:dateCreated2007-5-8lld:pubmed
pubmed-article:17484137pubmed:abstractTextHuman Immunodeficiency Virus type 1 (HIV-1) infection can now be treated effectively in many patients in the developed world, using combinations of antiretroviral therapeutics, called Highly Active Anti-Retroviral Therapy (HAART). However, despite prolonged treatment with HAART, the persistence of latently HIV-1-infected cellular reservoirs harboring transcriptionally silent but replication-competent proviruses represents the major hurdle to virus eradication. These latently infected cells are a permanent source for virus reactivation and lead to a rebound of the viral load after interruption of HAART. Therefore, a greater understanding of the molecular mechanisms regulating proviral latency and reactivation should lead to rational strategies aimed at purging these cellular reservoirs of HIV-1. This review summarizes our current knowledge and understanding of the elements involved in HIV-1 transcriptional reactivation: (1) the site of integration; (2) the transcription factor NF-kappaB, which is induced by proinflammatory cytokines (such as TNFalpha) and binds to two kappaB sites in the HIV-1 promoter region; (3) the specific remodeling of a single nucleosome (called nuc-1 and located immediately downstream of the HIV-1 transcription start site under latency conditions) upon activation of the HIV-1 promoter; (4) post-translational acetylation of histones and of non-histone proteins (following treatment with deacetylases inhibitors, which induce viral transcription and nuc-1 remodeling); and (5) the viral trans-activator Tat, which promotes transcription by mediating the recruitment to the HIV-1 promoter of histone-modifying enzymes and ATP-dependent chromatin remodeling complexes required for nucleosome disruption and transcriptional processivity. Finally, this review highlights experimental therapies aimed at administrating HIV-1 gene expression activators (such as HDAC inhibitors) combined with an effective HAART in order to reactivate and decrease/eliminate the pool of latently HIV-1-infected cellular reservoirslld:pubmed
pubmed-article:17484137pubmed:languageenglld:pubmed
pubmed-article:17484137pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17484137pubmed:citationSubsetIMlld:pubmed
pubmed-article:17484137pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17484137pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17484137pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17484137pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17484137pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17484137pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17484137pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17484137pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17484137pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17484137pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17484137pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17484137pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17484137pubmed:statusMEDLINElld:pubmed
pubmed-article:17484137pubmed:issn0306-0225lld:pubmed
pubmed-article:17484137pubmed:authorpubmed-author:Van...lld:pubmed
pubmed-article:17484137pubmed:authorpubmed-author:QuivyVincentVlld:pubmed
pubmed-article:17484137pubmed:authorpubmed-author:De...lld:pubmed
pubmed-article:17484137pubmed:issnTypePrintlld:pubmed
pubmed-article:17484137pubmed:volume41lld:pubmed
pubmed-article:17484137pubmed:ownerNLMlld:pubmed
pubmed-article:17484137pubmed:authorsCompleteYlld:pubmed
pubmed-article:17484137pubmed:pagination371-96lld:pubmed
pubmed-article:17484137pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:17484137pubmed:meshHeadingpubmed-meshheading:17484137...lld:pubmed
pubmed-article:17484137pubmed:meshHeadingpubmed-meshheading:17484137...lld:pubmed
pubmed-article:17484137pubmed:meshHeadingpubmed-meshheading:17484137...lld:pubmed
pubmed-article:17484137pubmed:meshHeadingpubmed-meshheading:17484137...lld:pubmed
pubmed-article:17484137pubmed:meshHeadingpubmed-meshheading:17484137...lld:pubmed
pubmed-article:17484137pubmed:meshHeadingpubmed-meshheading:17484137...lld:pubmed
pubmed-article:17484137pubmed:meshHeadingpubmed-meshheading:17484137...lld:pubmed
pubmed-article:17484137pubmed:meshHeadingpubmed-meshheading:17484137...lld:pubmed
pubmed-article:17484137pubmed:meshHeadingpubmed-meshheading:17484137...lld:pubmed
pubmed-article:17484137pubmed:meshHeadingpubmed-meshheading:17484137...lld:pubmed
pubmed-article:17484137pubmed:meshHeadingpubmed-meshheading:17484137...lld:pubmed
pubmed-article:17484137pubmed:meshHeadingpubmed-meshheading:17484137...lld:pubmed
pubmed-article:17484137pubmed:meshHeadingpubmed-meshheading:17484137...lld:pubmed
pubmed-article:17484137pubmed:meshHeadingpubmed-meshheading:17484137...lld:pubmed
pubmed-article:17484137pubmed:meshHeadingpubmed-meshheading:17484137...lld:pubmed
pubmed-article:17484137pubmed:meshHeadingpubmed-meshheading:17484137...lld:pubmed
pubmed-article:17484137pubmed:meshHeadingpubmed-meshheading:17484137...lld:pubmed
pubmed-article:17484137pubmed:meshHeadingpubmed-meshheading:17484137...lld:pubmed
pubmed-article:17484137pubmed:meshHeadingpubmed-meshheading:17484137...lld:pubmed
pubmed-article:17484137pubmed:meshHeadingpubmed-meshheading:17484137...lld:pubmed
pubmed-article:17484137pubmed:meshHeadingpubmed-meshheading:17484137...lld:pubmed
pubmed-article:17484137pubmed:meshHeadingpubmed-meshheading:17484137...lld:pubmed
pubmed-article:17484137pubmed:year2007lld:pubmed
pubmed-article:17484137pubmed:articleTitleChromatin-associated regulation of HIV-1 transcription: implications for the development of therapeutic strategies.lld:pubmed
pubmed-article:17484137pubmed:affiliationUniversity Libre de Bruxelles, Institut de Biologie et de Médecine Moléculaíres, Laboratoire de Virologie Moléculaire, 12, rue des Professeurs Jeener et Brachet 6041 Gosselies, Belgium.lld:pubmed
pubmed-article:17484137pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17484137pubmed:publicationTypeReviewlld:pubmed
pubmed-article:17484137pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17484137lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17484137lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17484137lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17484137lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17484137lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17484137lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17484137lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17484137lld:pubmed